Join

Compare · NVO vs SPPI

NVO vs SPPI

Side-by-side comparison of Novo Nordisk A/S (NVO) and Spectrum Pharmaceuticals Inc. (SPPI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and SPPI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $187.53B, about 1647.6x SPPI ($113.8M).
  • NVO has hit the wire 11 times in the past 4 weeks while SPPI has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 1 for SPPI).
MetricNVOSPPI
Company
Novo Nordisk A/S
Spectrum Pharmaceuticals Inc.
Price
$42.01-2.10%
$1.03+0.49%
Market cap
$187.53B
$113.8M
1M return
-5.38%
-
1Y return
-40.76%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
11
0
Recent ratings
25
1
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

SPPI

Spectrum Pharmaceuticals Inc.

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.